New Standard When HER2+ Breast Cancer Isn't Cleared New Standard When HER2+ Breast Cancer Isn't Cleared
' Practice-changing'results support adjuvant trastuzumab emtansine in patients with HER2+ early stage breast cancer who have residual disease following surgery.Medscape Medical News
Publication date: Available online 23 March 2019Source: European Journal of Surgical OncologyAuthor(s): Paul Savage, Nancy Yu, Sinziana Dumitra, Sarkis MeterissianAbstractIntroductionBreast cancer staging has been developed to quantify prognosis and guide treatment. The American Joint Committee on Cancer eighth edition manual (AJCC8) departed from traditional anatomic staging by incorporating biological factors such as grade, hormone and HER2 receptor status into a novel prognostic staging model. The aim of this study was to externally validate AJCC8 prognostic staging.MethodsThis retrospective cohort investigated patients...
ConclusionThis case highlights the importance of using caution when combining radiation with the new targeted therapies. Until more data becomes available, physicians are recommended to exercise clinical judgment when deciding on whether to continue or discontinue a CDK4/6 inhibitor in a patient who may need radiation.
Authors: Robert M, Frenel JS, Bourbouloux E, Berton Rigaud D, Patsouris A, Augereau P, Gourmelon C, Campone M Abstract INTRODUCTION: Pertuzumab, a humanized monoclonal antibody that binds the human epidermal growth factor receptor 2 (HER2), inhibits the heterodimerization of HER2 with other HER receptors. It has been approved both by the Food and Drug Administration and the European Medicine Agency in the metastatic, neoadjuvant and adjuvant setting. Areas covered: This review analyses and discusses preclinical and clinical studies of pertuzumab in breast cancer. In this article, we review the status of pertuzumab,...
ConclusionsWe applied a complete “white box” machine learning method to predict the molecular subtype of breast cancer based on the BI-RADS feature description in a multi-modal setting. By combining BI-RADS features in both mammography and MRI, the prediction accuracy is boosted and robust. The proposed method can be easily applied widely regardless of variability of imaging vendors and settings because of the applicability and acceptance of the BI-RADS.
Conclusions: S-1 can be safely combined with the clinically relevant dose of T-DM1 in patients with HER2-positive advanced or metastatic breast cancer. Further evaluation with a larger sample size is required for efficacy assessment.Oncology
Condition: HER2-positive Breast Cancer Interventions: Drug: TAHP and AHP; Drug: TAHP plus AC and AHP Sponsor: Samsung Medical Center Not yet recruiting
CONCLUSIONS: HER2 GH is an infrequent event, may contain morphologic heterogeneity, could infer incomplete response to neoadjuvant therapy, and requires adequate communication with treating clinicians. PMID: 30892594 [PubMed - as supplied by publisher]
Burman P Abstract OBJECTIVE: To investigate the contemporary presentation of pituitary metastases. PATIENTS: Thirty-eight patients diagnosed with pituitary metastases 1996 to 2018 in Sweden. METHODS: Pituitary metastases were confirmed by histopathology (n = 27) or considered highly likely due to radiological findings, including rapid tumor progression (n = 11). Medical charts were reviewed and sellar images re-examined centrally. RESULTS: Breast and lung cancer were the most common primary tumors, 45% and 21% of the patients. The pituitary was the only metastatic site in 9 patients. 67% of the bre...
CONCLUSIONS: S-1 can be safely combined with the clinically relevant dose of T-DM1 in patients with HER2-positive advanced or metastatic breast cancer. Further evaluation with a larger sample size is required for efficacy assessment. PMID: 30893699 [PubMed - as supplied by publisher]
Conditions: Breast Cancer; Breast Cancer Female; HER2-positive Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III Interventions: Drug: Docetaxel; Drug: Herceptin; Drug: FEC; Drug: Tamoxifen; Drug: Letrozole; Drug: LHRH agonist Sponsor: University of Chicago Not yet recruiting